Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

55X_ROI_Q1_2026 Jun. 25 at 9:21 PM

$SLS https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results $ABBV Modified the VIALE-M Phase 3 SAP 7 times. - you can see. 7 times TRYING to find a regime that worked, and was not Toxic, Varying Reduced Aza / Varying Reduced VEN All ORAL, IV and Subq --- all Failed --- BAT is Toxic. Meanwhile REGAL Phase 3 Trial Clinicians Requested Expanded Access and Extended Dosing ---- Buy and Hold as many as You can. - it is not complicated $GLSI

0 · Reply

Game_Day Jun. 25 at 8:26 PM

June 25 Thank gd much better today Highlights / alerts $ABT $ABBV $BNC $CRM

0 · Reply

ApexEquityVault Jun. 25 at 7:57 PM

$0.72 on $ABBV here! 🩺 67% return! 🔥

0 · Reply

StockpeakHQ_1 Jun. 25 at 7:54 PM

$0.72 on $ABBV here! 67% return

0 · Reply

biolover Jun. 25 at 7:24 PM

$VKTX Been watching $ABBV meteoric rise post apge deal. Listening to CMO shows some confusion re obesity mechanisms etc. rumor ABBV was looking for same molecule as $NVO …. Abbv could make market rerating of large pharma valuations with a serious obesity M&A and pose serious competition to $LLY But my sense they don’t command good understanding of the field to do that.

1 · Reply

genomanetti Jun. 25 at 6:55 PM

$ABBV baked in revenue plus new medicine initiatives and strong cash flow plus sustain predictable dividends.

0 · Reply

Noxcapitaltrade Jun. 25 at 6:43 PM

$ABBV $0.63 on $ABBV here! 🩺 46% return! 🔥

0 · Reply

LUXtrades0 Jun. 25 at 6:40 PM

$ABBV 245 CALL 6/26 @ 1.80

0 · Reply

leifstocks Jun. 25 at 6:39 PM

$ABBV 245 CALL 6/26 @ 1.80

0 · Reply

Snipertradesexpert Jun. 25 at 6:38 PM

$ABBV 245 CALL 6/26 @ 1.80

0 · Reply

AbbVie's $11 Billion Immunology Bet

APGE

Jun 24, 2026, 8:00 AM EDT - 1 day ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

2026-06-23T12:54:44.000Z - 2 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:22:00.000Z - 2 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Jun 23, 2026, 8:00 AM EDT - 2 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

2026-06-23T11:29:50.000Z - 2 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

2026-06-23T11:04:51.000Z - 2 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

2026-06-23T10:24:35.000Z - 2 days ago

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:00:54.000Z - 2 days ago

AbbVie announces European Commission approval of Maviret

2026-06-23T09:46:03.000Z - 2 days ago

AbbVie announces EU approval of Skyrizi for pediatric patients

Jun 23, 2026, 5:00 AM EDT - 2 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 3:00 AM EDT - 2 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

2026-06-22T21:55:09.000Z - 3 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Jun 22, 2026, 10:30 AM EDT - 3 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

Jun 22, 2026, 10:15 AM EDT - 3 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

Jun 22, 2026, 9:00 AM EDT - 3 days ago

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 3 days ago

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 3 days ago

AbbVie Press release: M&A announcement

2026-06-22T12:24:03.000Z - 3 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

Jun 22, 2026, 7:42 AM EDT - 3 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

2026-06-22T11:15:52.000Z - 3 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE

2026-06-22T11:10:51.000Z - 3 days ago

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

APGE

Jun 22, 2026, 7:06 AM EDT - 3 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

Jun 22, 2026, 7:04 AM EDT - 3 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

Jun 22, 2026, 7:00 AM EDT - 3 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

2026-06-22T10:48:07.000Z - 3 days ago

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

APGE CLDX CNTB EVMN KYMR NKTR

2026-06-22T10:40:59.000Z - 3 days ago

BTIG says others may be interested in Apogee Therapeutics

APGE CBIO JBIO JNJ NVS ORKA PFE

2026-06-22T10:23:29.000Z - 3 days ago

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

APGE REGN

2026-06-22T09:00:15.000Z - 3 days ago

AbbVie near deal to acquire Apogee Therapeutics, FT reports

APGE

2026-06-22T05:55:55.000Z - 3 days ago

‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition

APGE REGN SNY

Jun 20, 2026, 12:11 PM EDT - 5 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

Jun 19, 2026, 11:17 AM EDT - 6 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Jun 18, 2026, 4:05 PM EDT - 7 days ago

AbbVie Declares Quarterly Dividend

Jun 16, 2026, 8:00 AM EDT - 9 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 12, 2026, 3:00 AM EDT - 13 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 11, 2026, 7:14 AM EDT - 14 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

Jun 10, 2026, 11:47 AM EDT - 15 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 9, 2026, 10:40 AM EDT - 16 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 17 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 3, 2026, 7:04 PM EDT - 22 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 3:30 AM EDT - 22 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

Jun 2, 2026, 8:00 AM EDT - 23 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 29, 2026, 8:00 AM EDT - 27 days ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 4 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug

May 22, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 21, 2026, 6:46 PM EDT - 5 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 4:10 PM EDT - 5 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 13, 2026, 2:20 PM EDT - 6 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 5, 2026, 8:05 AM EDT - 7 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

May 1, 2026, 3:05 PM EDT - 7 weeks ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 7 weeks ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 2 months ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 2 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 2 months ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 2 months ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 8, 2026, 1:38 PM EDT - 2 months ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

55X_ROI_Q1_2026 Jun. 25 at 9:21 PM

0 · Reply

Game_Day Jun. 25 at 8:26 PM

June 25 Thank gd much better today Highlights / alerts $ABT $ABBV $BNC $CRM

0 · Reply

ApexEquityVault Jun. 25 at 7:57 PM

$0.72 on $ABBV here! 🩺 67% return! 🔥

0 · Reply

StockpeakHQ_1 Jun. 25 at 7:54 PM

$0.72 on $ABBV here! 67% return

0 · Reply

biolover Jun. 25 at 7:24 PM

1 · Reply

genomanetti Jun. 25 at 6:55 PM

$ABBV baked in revenue plus new medicine initiatives and strong cash flow plus sustain predictable dividends.

0 · Reply

Noxcapitaltrade Jun. 25 at 6:43 PM

$ABBV $0.63 on $ABBV here! 🩺 46% return! 🔥

0 · Reply

LUXtrades0 Jun. 25 at 6:40 PM

$ABBV 245 CALL 6/26 @ 1.80

0 · Reply

leifstocks Jun. 25 at 6:39 PM

$ABBV 245 CALL 6/26 @ 1.80

0 · Reply

Snipertradesexpert Jun. 25 at 6:38 PM

$ABBV 245 CALL 6/26 @ 1.80

0 · Reply

Blockwave1 Jun. 25 at 6:32 PM

$0.60 on $ABBV here! 🌊40% return! 🔥

0 · Reply

Noxcapitaltrade Jun. 25 at 6:31 PM

$ABBV $0.60 on $ABBV here! 🩺 40% return! 🔥

0 · Reply

55X_ROI_Q1_2026 Jun. 25 at 6:20 PM

$SLS IDMC ALREADY UNBLINDED ACTUAL PHASE 3 MOS AND IR DATA from the INTERIM ANALYSIS at 60 EVENTS... - SMARTER MONEY THAN US KNOWS GPS IS THE REASON WE CONTINUE TO WAIT FOR NEAR MIRACULOUS EXTENDED SURVIVAL DATA. BAT $ABBV FAILED - 4 RECENT TRIALS - 3 for AML REMISSION MAINTENANCE.

1 · Reply

LiveTradePro Jun. 25 at 5:40 PM

$ABBV Beautiful breakout https://share.trendspider.com/chart/ABBV/6682tsexcw

0 · Reply

55X_ROI_Q1_2026 Jun. 25 at 5:10 PM

$SLS https://www.reddit.com/r/sellasLifescience/ Anyone interested in Money should be attempting to Quantify GPS Value --- What is GPS Worth? https://www.reddit.com/r/sellasLifescience/ $28B Total Addressable Market Imminently due Phase 3 Results will give Gps the FDA Green Light to Generate 10's of Billions in Real Dollars --- Do not Be Surprised if we see $ABBV PR trying to Buy SLS CHeap for $30B. --- will be Massive Class Action for Selling too Cheap

0 · Reply

55X_ROI_Q1_2026 Jun. 25 at 4:54 PM

$SLS $ABVX $ABBV pardon me for the error: Aza+VEN Failed 2 Phase 3 AML Remission Maintenance trials, and just weeks ago - a Phase 2 - low intensity, all oral P2 Aza Ven Trial Failed.

0 · Reply

55X_ROI_Q1_2026 Jun. 25 at 4:29 PM

$SLS $ABVX and for the short boys in the back... $ABBV Knows BAT Doesn't work and that its GPS doing what its done in all Prior trials.... Aza+VEN / BAT for Control ARM patients in the SLS REGAL Trial, Recently FAILED 3 Large Phase 3 Trials - Including 2 for AML Remission Maintenance. VIALE-M Phase 3 for First Remission CR1 Maintenance FAILED VIALE-T Phase 3 For Post Transplant Maintenance FAILED VERONA - High Risk MDS/AML Precursor FAILED Phase 2 Aza+VEN all oral, Low dose - FAILED - results at Ash.... ITS GPS DOING WHAT ITS DONE IN ALL 7 Trials including 2 for AML REMISSION MAINTENANCE.

0 · Reply

liamsniperalert Jun. 25 at 4:24 PM

0.57 on $ABBV here! 32% return! 🏆🗻

0 · Reply

PanicSeller8 Jun. 25 at 3:17 PM

$ABBV Quite the run!

0 · Reply

liamsniperalert Jun. 25 at 2:46 PM

$ABBV 02 JUL 26 $255 CALL $0.43 PIVOT BREAKOUT + ALL-TIME HIGH BREAKOUT SETUP + RELATIVE STRENGTH + SECTOR SENTIMENT + SENTIMENT ANALYSIS + PRICE UPGRADE

0 · Reply

Noxcapitaltrade Jun. 25 at 2:46 PM

$ABBV 02 JUL 26 $255 CALL $0.43

0 · Reply

ApexEquityVault Jun. 25 at 2:46 PM

$ABBV 02 JUL 26 $255 CALL $0.43 PIVOT BREAKOUT + ALL-TIME HIGH BREAKOUT SETUP + RELATIVE STRENGTH + SECTOR SENTIMENT + SENTIMENT ANALYSIS + PRICE UPGRADE

0 · Reply

Market Cap	406.38B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	22.57
Forward PE	16.08
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	10,281,743
Avg Vol	6,212,310
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	89%
Beta	0.32
Analysts	Strong Sell
Price Target	$251.83